Figure 1: Population-averaged probability (with 95% CI) of SHI and PHI patients receiving sumatriptan compared with nonserotoninergic migraine attack therapy. The probability of receiving sumatriptan was lower for SHI patients than PHI patients. Adapted from Medical Care 2004; 42(5): 487-491. 2004, Lippincott Williams & Wilkins © .